Moderna's COVID-19 Vaccine Candidate To Enter Phase 3 Trial

Moderna's preliminary vaccine trials showed promising results, with all 45 participants developing antibodies against COVID-19. The trial involved administering the vaccine twice at varying dosages, with higher dosages yielding stronger antibodies. Side effects were mild, including pain at the injection site, headache, chills, and muscle pain. Unlike traditional vaccines, Moderna's uses mRNA to trigger an immune response. The vaccine may offer protection for up to two years. Phase three of the trial is set to begin on July 27th with 30,000 participants.

What new insight or understanding did you gain from this video?